VNVC launched mass dengue fever vaccination using Takeda's Qdenga, effective against all four dengue virus types, reducing hospitalization risk by 90%. The vaccine, approved in May 2024, is crucial for Vietnam due to high reinfection rates. VNVC, a strategic partner with Takeda, aims to reduce dengue's disease burden. Dengue, a WHO top 10 global health threat, has increased tenfold since 2000, with Vietnam ranking second globally in 2022 cases.